Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity
Objective: To identify disease-modifying therapy for LRRK2-G2019S parkinsonism. Background: Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD) without…The CNS moving voice program: Implementation of a dual voice and physical exercise program for Parkinson’s disease: An applicability study
Objective: To test the applicability of a rehabilitation program for people with Parkinson´s disease that combines speech and motor exercises (The CNS Moving Voice Program).…Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: The objective was to determine whether Nilotinib crosses the blood brain barrier (BBB). Background: Parkinson's disease (PD) involves death of dopamine producing neurons in…Patient case reports supporting a long-term effect of sub-anesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias
Objective: To evaluate possible long-term anti-dyskinetic activity of low-dose sub-anesthetic ketamine infusion from a retrospective chart review. Background: Repurposing drugs that have already been proven…Best supportive care or palliative care for late stage Parkinsonian syndromes?
Objective: To ask whether best supportive care might be more suitable for patients with Parkinson's disease (PD) and Parkinsonian syndromes and their family than palliative…Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study
Objective: To evaluate long-term efficacy, levodopa dose changes and complications in patients with advanced Parkinson's disease (PD) treated. Background: Administrated via percutaneous gastric gastrostomy to…Effect of patient characteristics on motor function in response to 35–50 mg of inhaled levodopa (CVT-301) in patients with Parkinson’s disease: Results from a phase 2b study
Objective: To examine whether the response to an inhaled levodopa formulation (CVT-301; at 35 and 50 mg per dose) is dependent on baseline patient characteristics.…Improved motor functioning of people with Parkinson’s disease following dance intervention
Objective: To investigate the effectiveness of dance as an additional treatment for people with Parkinson's disease (PD). Background: Common pharmacological treatments for PD lessen the…Objective measures of Parkinsonian motor symptoms using a continuously worn smartwatch
Objective: To determine whether smartwatch sensor data correlates with clinician-measured Parkinson's disease symptoms. Background: Data collected with smartwatches could be used for long-term, continuous assessment…Safety and tolerability of inhaled levodopa (CVT-301) administered to Parkinson’s disease patients with motor fluctuations
Objective: Two Phase 2 studies were conducted to evaluate the safety profile of inhaled CVT-301 administered to Parkinson's disease (PD) patients with motor fluctuations. Background:…
- « Previous Page
- 1
- …
- 136
- 137
- 138
- 139
- 140
- …
- 207
- Next Page »